Ernexa Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ERNA Nasdaq 2836 www.ernexatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ernexa Therapeutics Inc.

Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development - May 27th, 2026 6:11 am
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know - May 20th, 2026 8:45 am
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity - May 20th, 2026 6:31 am
Trump Rattled Markets Again and These 3 Forgotten Stocks Under $30 Were the Unlikely Winners - May 18th, 2026 8:35 am
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101 - May 11th, 2026 7:15 am
Ernexa Therapeutics (ERNA) Preclinical Data Shows 100% Survival and Complete Tumor Clearance in Ovarian Cancer Models - May 6th, 2026 8:40 am
Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models - May 6th, 2026 6:33 am
Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split - Apr 30th, 2026 7:00 am
Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026 - Mar 31st, 2026 6:55 am
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series - Feb 20th, 2026 7:05 am
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering - Feb 6th, 2026 7:25 am
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA - Feb 3rd, 2026 6:45 am
Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program - Jan 27th, 2026 6:45 am
Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer - Jan 6th, 2026 6:15 am
Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer - Dec 8th, 2025 6:30 am
Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting - Dec 3rd, 2025 6:30 am
Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG - Dec 2nd, 2025 6:50 am
Ernexa Therapeutics to Present at Oxford Global’s Cell 2025 - Nov 11th, 2025 5:00 am
Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials - Nov 10th, 2025 6:35 am
Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform - Nov 6th, 2025 7:15 am